目的 研究新辅助化疗（NACT）后接受手术的恶性卵巢生殖细胞肿瘤（MOGCT）患者的临床特征和结局。对我所进行 NACT 后接受手术的 MOGCT 患者进行回顾性研究。 NACT中所有患者均接受铂类化疗。2013年3月至2023年2月期间，30名患者在NACT后接受了手术。患者的中位年龄为 22 岁（范围为 12 至 35 岁），中位随访时间为 42 个月（范围为 6 至 132 个月）。大多数患有内胚窦肿瘤（n = 12）、无性细胞瘤（n = 9）和混合性GCT（n = 7）。所有患者均患有国际妇产科联合会 (FIGO) 3 期疾病 (n=19) 或国际妇产科联合会 4 期疾病 (n=11)。 5 名患者对 NACT 完全缓解，23 名患者部分缓解。 18 名患者进行了保留生育手术，12 名患者完成了手术。 4 名患者的手术效果不佳。目前，30 名患者中有 20 名存活且无病，3 名患者失访，7 名患者在辅助治疗后出现病情进展。 5 名患者死亡，其中 4 名患者因疾病进展而死亡，1 名患者因博来霉素中毒而死亡。 17 名符合条件的患者中，15 名已恢复月经，1 名成功怀孕。研究中指出的预后因素包括分期、最佳手术和组织病理学中存活的肿瘤。无性细胞瘤的结果优于其他组织学。对于患有广泛的不可切除疾病或不可能保留生育能力或一般状况不佳的患者，NACT 可能是一个合理的选择。新辅助化疗后可以尝试保留生育能力手术，而不会对预后产生不利影响。© 2023。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

To study clinical characters and outcomes in patients of malignant ovarian germ cell tumor (MOGCT) undergoing surgery following neoadjuvant chemotherapy (NACT).Retrospective study of patients undergoing surgery following NACT for MOGCT at our institute. Platinum based chemotherapy was given in all patients in NACT.Between March 2013 and February 2023, 30 patients had surgery after NACT. Patient's median age was 22 years (range, 12 to 35 years) and median follow up 42months (range, 6 to 132 months). Majority had endodermal sinus tumor (n=12), dysgerminoma (n=9) and mixed GCT (n=7). All had either International Federation of Gynecology and Obstetrics (FIGO) stage 3 (n=19) or FIGO stage 4 disease (n=11). Complete response to NACT seen in 5 patients and 23 patients had partial response. Fertility sparing surgery in 18 patients and complete surgery in 12 patients. Suboptimal surgery was seen in 4 patients. Currently, 20 of 30 patients are alive and disease free, 3 lost for follow up and 7 patients had progression after adjuvant therapy. Five patients had mortality-4 with progression and 1 with bleomycin toxicity. Fifteen of 17 eligible patients have resumed menstruation and one had successful pregnancy. Prognostic factors noted in study are stage, optimal surgery and viable tumor in histopathology. Dysgerminoma had better outcome than other histology.NACT may be a reasonable option in patients with extensive unresectable disease or in whom fertility sparing is not possible or in the poor general condition. Fertility sparing surgery can be attempted post neoadjuvant chemotherapy without adversely affecting prognosis.© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.